Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2005

View Archived Issues

A new drug delivery system for the selective targeting of paclitaxel

Sodium pyruvate provides neuroprotection following severe hypoglycemic shock

Xanthohumol represents a new cancer therapy for hypoxic tumors

Preclinical and clinical data presented on AG-013958

Data presented on VEGF Trap: a potential treatment for neovascular eye disease

Medivir offers first quarter interim report

Cambridge Biostability signs agreement for Acambis' HolaVax-ETEC vaccine

Elevated levels of immunomodulatory IDO mediate adalimumab psoriasis therapy

FDA extends review date of dalbavancin NDA

Genta and Aventis terminate Genasense agreement

Crompton and Great Lakes Chemical to form Chemtura

CYT009-GhrQb enters phase I/II trial for obesity

CP-31398 suppresses UVB-induced squamous cell carcinoma in hairless mice via activation of p53

Topical NF-kappaB Decoy: safe and effective in animal models of atopic dermatitis

Sebocytes: novel target cells for active vitamin D analogues

Novel antidiabetic agents imparted in recent patents

Phase II data support the use of APD-356 in the management of obesity

Ono and Medarex to develop anti-PD-1 antibody for cancer

Patents describe therapeutic agents for gastrointestinal and liver disorders

SCRAS reports use of botulinum toxin for respiratory distress

Prasterone significantly increases bone mineral density in female lupus patients

Ixabepilone administered daily for three consecutive days well tolerated in phase I study

Encouraging results for pirfenidone in idiopathic pulmonary fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...